NM
Nina Mufti

Well Cited

54
Works
453
Citations
11
H-Index
Search Authors
Author Statistics
  • OpenAlex ID A5048660321
  • i10-Index 13
  • 2-Yr Mean Citedness 0.00
External Links
OpenAlex Profile

Nina Mufti

Also known as: Mufti, Nina, N. Mufti, N.A. Mufti, Nina A. Mufti, Nina Mufti

54

Total Works

453

Citations

11

H-Index

13

i10-Index

Citation & Works Trend by Year
19 years active
Top Research Topics
Blood transfusion and management (50) Blood groups and transfusion (21) Trauma, Hemostasis, Coagulopathy, Resuscitation (19) Blood donation and transfusion practices (11) Microbial Inactivation Methods (10)
Recent Publications
15 shown
Year Publication Title Citations Action
2026 A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)—protocol for a phase 3 clinical trial Trials 0
2026 A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)—protocol for a phase 3 clinical trial Figshare 0
2026 Additional file 1 of A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)—protocol for a phase 3 clinical trial Figshare 0
2026 Safety and tolerability of amustaline/glutathione pathogen‐reduced red blood cells in neonatal rats Transfusion 0
2025 A Randomized, Double-Blind, Controlled, Parallel Group Study with Amustaline/Glutathione Pathogen Reduced Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS Study): -- Protocol for a Phase 3, Randomized, Controlled Trial Research Square 0
2025 Amustaline/glutathione pathogen‐reduced red cell hemoglobin utilization in complex cardiac surgery: A post hoc analysis of the phase 3 ReCePI trial Transfusion 1
2025 Effects of an amustaline (S‐303)/glutathione pathogen reduction system on the in vitro quality of plasma and platelets in treated whole blood Transfusion 1
2025 Impact of whole blood amustaline pathogen inactivation on plasma coagulation factor activity; Mechanism of action Blood 0
2025 Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model Transfusion 1
2025 A novel acridine flow cytometry marker to track post‐transfusion amustaline/glutathione pathogen‐reduced red blood cell survival in sickle cell disease patients Transfusion 5
2025 Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen‐reduced red cells in complex cardiac surgery patients Transfusion 2
2024 Characterizing the antibody response to amustaline/glutathione pathogen‐reduced red blood cells Transfusion 9
2024 Tracking Entire Units of Transfused Pathogen-Reduced Red Cells in Sickle Cell Patients Using a Novel Acridine Marker Blood 0
2024 Transfusion Efficacy and Safety of Amustaline/Glutathione Pathogen-Reduced Red Blood Cells: Results of a Randomized, Controlled Phase III Trial Blood 0
2024 In vivo genotoxicity assessment of N‐(‐9 acridinyl)‐b‐alanine hydrochloride ( S‐300 ) using a validated Pig‐a mutagenesis assay Transfusion 3

Data source: OpenAlex API